{"id":"NCT01174004","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis","officialTitle":"A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2010-08-03","resultsPosted":"2014-03-26","lastUpdate":"2014-03-26"},"enrollment":199,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease Psychosis"],"interventions":[{"type":"DRUG","name":"pimavanserin tartrate","otherNames":["ACP-103"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).","primaryOutcome":{"measure":"Antipsychotic Efficacy","timeFrame":"Each study visit (i.e. Days 1, 15, 29 and 43)","effectByArm":[{"arm":"Placebo","deltaMin":-2.73,"sd":null},{"arm":"Pimavanserin 40 mg","deltaMin":-5.79,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":63,"countries":["United States","Canada"]},"refs":{"pmids":["24183563"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":94},"commonTop":["Urinary tract infection","Fall","Nausea","Edema peripheral","Confusional state"]}}